Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWBYK 191023 is an L-arginine competitive and selective inhibitor of inducible nitric oxide synthase (iNOS) with IC50 values of 0.086, 17, and 162 μM for human recombinant iNOS, nNOS, and eNOS, respectively.1 It also inhibits murine recombinant iNOS (IC50 = 95 nM). BYK 191023 inhibits iNOS-induced nitrite generation in RMC, RAW, and HEK293 cells (IC50s = 33, 3.1, and 13 μM, respectively). In vivo, BYK 191023 suppresses LPS-induced increases in plasma nitrate and nitrite levels in rats (ED50 = 14.9 μmol/kg per hour).2 It prevents development of delayed hypotension in a rat model of LPS-induced endotoxemia when administered at a dose of 50 μmol/kg per hour. BYK 191023 also increases mean arterial pressure and renal blood flow in a sheep model of septic shock.3
WARNING This product is not for human or veterinary use.
1. The novel imidazopyridine 2-
2. In vivo characterization of the novel imidazopyridine BYK191023 [2-
3. Effects of a selective iNOS inhibitor versus norepinephrine in the treatment of septic shock. Shock 34(3), 243-249 (2010).